BG
BBNX

Bellevue Group’s Beta Bionics BBNX Stock Holding History

Bellevue Group’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$723K Sell
72,152
-133
-0.2% -$1.97K 0.02% 101
2025
Q4 		$2.2M Buy
72,285
+8,002
+12% +$214K 0.04% 94
2025
Q3 		$1.28M Sell
64,283
-2,542
-4% -$44.7K 0.03% 103
2025
Q2 		$973K Hold
66,825
– – 0.02% 104
2025
Q1 		$818K Buy
+66,825
New +$1.25M 0.02% 111

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bellevue Group's BBNX Position: Q1 2026 in Review

Bellevue Group reduced its Beta Bionics (BBNX) stake by 0.18% in Q1 2026, selling an estimated $1.97K and leaving 72,152 shares worth $723K. The position accounts for 0.02% of the portfolio, ranked #101.

Bellevue Group first reported a position in BBNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.2M in Q4 2025. 130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Bellevue Group held 72,152 shares of Beta Bionics worth $723K as of Q1 2026.
  • Bellevue Group sold 133 Beta Bionics shares in Q1 2026, an estimated $1.97K.
  • Beta Bionics made up 0.02% of Bellevue Group's portfolio in Q1 2026, its #101 holding.
  • Bellevue Group first reported a position in Beta Bionics in Q1 2025 and has held it in 5 quarters since.
  • Bellevue Group's Beta Bionics position peaked at $2.2M in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.